Nuances of new anti-Aspergillus antifungals

References

• Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33: 1824–1833
   PubMed Web of Science ®Google Scholar
• Denning DW, Marinus A, Cohen J, et al. An EORTC multicenter prospective survey of invasive aspergillosis in hematological patients: Diagnosis and therapeutic outcome. J Infect 1998; 37: 173–180
   PubMed Web of Science ®Google Scholar
• Schwartz S, Thiel E. Update on the treatment of cerebral aspergillosis. Ann Hematol 2004; 83(Suppl 1)S42–S44
   Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case fatality rate: systemic review of the literature. Clin Infect Dis 2001; 32: 366
   Google Scholar
• Davis GM, Dasbach EJ, Teutsch SM. The burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000; 31: 1524–1528
   Google Scholar
• Fukuda T, Boeckh M, Guthrie KA, et al. Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004; 10: 494–503
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366
   PubMed Web of Science ®Google Scholar
• von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62: 341–347
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641–649
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199–205
   PubMed Web of Science ®Google Scholar
• Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 39: 1504–1512
   Google Scholar
• Adam O, Auperin A, Wilquin F, et al. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917–920
   PubMed Web of Science ®Google Scholar
• Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253–259
   PubMed Web of Science ®Google Scholar
• Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139–147
   PubMed Web of Science ®Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37(Suppl 3)S157–S187
   PubMedGoogle Scholar
• Meyers J, Nemunaitis J, Shannon-Dorcy K, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993; 82: 1422–1427
   Google Scholar
• Linden P, Coley K, Kramer D, Kusne S, Fung J. Invasive aspergillosis in liver transplant recipients: Comparison of outcome with amphotericin B lipid complex and conventional amphotericin B therapy. Transplantation 1999; 67: 232
   Google Scholar
• Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK, Jr., Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192–198
   PubMed Web of Science ®Google Scholar
• Balajee SA, Weaver M, Imhof A, Gribskov J, Marr KA. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother 2004; 48: 1197–1203
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Meletiadis J, Tortorano AM, et al. Susceptibility testing of sequential isolates of Aspergillus, fumigatus recovered from treated patients. J Med Microbiol 2004; 53: 129–134
   PubMed Web of Science ®Google Scholar
• Drew RH, Dodds AE, Benjamin DK, Jr., et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232–237
   PubMed Web of Science ®Google Scholar
• Yeghen T, Kibbler CC, Prentice HG, et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000; 31: 859–868
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527–1533
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705–713
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–414
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less common, emerging or refractory fungal infections. Clin Infect Dis 2003; 36: 1122–1131
   PubMed Web of Science ®Google Scholar
• Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693–715
   PubMed Web of Science ®Google Scholar
• Perea S, Gonzalez G, Fothergill AW, et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002; 46: 3039–3041
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564–2568
   PubMed Web of Science ®Google Scholar
• Sivak O, Bartlett K, Risovic V, et al. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC) Abelcet. in combination with caspofungin in experimental systemic aspergillosis. J Pharm Sci 2004; 93: 1382–1389
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834–1843
   PubMed Web of Science ®Google Scholar
• Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025–1032
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37(Suppl 3)S188–S224
   Google Scholar
• Marr KA, Boeckh M, Carter RA, Woo Kim H, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797–802
   PubMed Web of Science ®Google Scholar